BTIG raised the firm’s price target on Masimo to $125 from $105 and keeps a Buy rating on the shares as part of a broader research note on Medical Technology. The sector has seen a strong resurgence in recent weeks, and the recovery is warranted following months of panicked selling related to GLP-1 fears, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MASI:
- Apple granted motion for interim stay in Watch fight with ITC, Masimo
- Apple wins bid to pause Watch ban at U.S. appeals court, Reuters reports
- Masimo down 5% after Apple granted pause of Watch ban
- U.S. appeals court grants Apple pause of Apple Watch ban, Reuters reports
- Apple (NASDAQ:AAPL) Takes on Watch Ban